Pharmacological treatment of Alzheimer’s Disease
Aging Clinical and Experimental ResearchPublished 1 April 2006
Angelo Bianchetti, Piera Ranieri, Alessandro Margiotta, Marco Trabucchi
Citations68
SJR quartileQ2
SJR score1.14
SNIP1.17
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Although at present there is no cure for AD, several drug treatments and care strategies may improve or stabilize cognitive and behavioral symptoms, and improve the quality of life of patients and families.
Abstract
Although at present there is no cure for AD, several drug treatments and care strategies may improve or stabilize cognitive and behavioral symptoms, and improve the quality of life of patients and families.
Keywords
Computer ScienceMedicine
NaturePathways towards and away from Alzheimer's disease
3,037 Citations2004Mark P. Mattson
Rapid progress towards understanding the cellular and molecular alterations that are responsible for the neuron's demise may soon help in developing effective preventative and therapeutic strategies in Alzheimer's disease.
New England Journal of MedicineA Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
2,371 Citations1997Mary Sano, Christopher Ernesto +10 more
In patients with moderately severe impairment from Alzheimer's disease, treatment with selegiline or alpha-tocopherol slows the progression of disease.
JAMAMemantine Treatment in Patients With Moderate to Severe Alzheimer Disease Already Receiving Donepezil
1,375 Citations2004Pierre N. Tariot, Martin R. Farlow +5 more
In patients with moderate to severe AD receiving stable doses of donepezil, memantine resulted in significantly better outcomes than placebo on measures of cognition, activities of daily living, global outcome, and behavior and was well tolerated.
NeuronAntibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease
781 Citations2003Christoph Höck, Uwe Konietzko +15 more
It is established that antibodies against beta-amyloid plaques can slow cognitive decline in patients with Alzheimer's disease.
Archives of General PsychiatryOlanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities
600 Citations2000J. Street
Low-dose olanzapine (5 and 10 mg/d) was significantly superior to placebo and well tolerated in treating agitation/aggression and psychosis in this population of patients with AD.
PubMedEfficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
515 Citations2003Nhi‐Ha Trinh, Jennifer Hoblyn +2 more
It is indicated that cholinesterase inhibitors have a modest beneficial impact on neuropsychiatric and functional outcomes for patients with AD and future research should focus on how such improvements translate into long-term outcomes such as patient quality of life, institutionalization, and caregiver burden.
The Journal of Clinical PsychiatryA Randomized Placebo-Controlled Trial of Risperidone for the Treatment of Aggression, Agitation, and Psychosis of Dementia
464 Citations2003Henry Brodaty, David Ames +7 more
Treatment with low-dose risperidone resulted in significant improvement in aggression, agitation, and psychosis associated with dementia.
NeurologyEfficacy of donepezil in mild cognitive impairment
305 Citations2004Stephen Salloway, Steven H. Ferris +5 more
Although significant treatment effects were not seen in the primary efficacy measures, outcomes on secondary measures suggest promising directions for further evaluation of donepezil treatment in patients with MCI.
American Journal of PsychiatryAtypical Antipsychotics and Risk of Cerebrovascular Accidents
274 Citations2004Nathan Herrmann, Muhammad Mamdani +1 more
Olanzapine and risperidone use were not associated with a statistically significant increased risk of stroke compared with typical antipsychotic use.
American Journal of PsychiatryA Randomized, Placebo-Controlled Dose-Comparison Trial of Haloperidol for Psychosis and Disruptive Behaviors in Alzheimer’s Disease
238 Citations1998D. P. Devanand, Karen Marder +7 more
A favorable therapeutic profile for haloperidol in doses of 2-3 mg/day, although a subgroup developed moderate to severe extrapyramidal signs, may also apply to other neuroleptics used in Alzheimer's disease patients with psychosis and disruptive behaviors.
BMJAtypical antipsychotic drugs in the treatment of behavioural and psychological symptoms of dementia: systematic review
226 Citations2004Philip E. Lee, Sudeep S. Gill +4 more
Limited evidence supports the perception of improved efficacy and adverse event profiles compared with typical antipsychotic drugs in the management of the behavioural and psychological symptoms of dementia.
PubMedReducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.
220 Citations1998Gilbert Honigfeld, Félix Arellano +3 more
The estimated impact of the CNR on clozapine-related morbidity and mortality over the first 5 years of commercial experience in the United States is reviewed.
American Journal of Geriatric PsychiatryMetaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease
157 Citations2004Craig Ritchie
Dementia and Geriatric Cognitive DisordersDiagnosis and Treatment of Depression in Alzheimer’s Disease
135 Citations2003Constantine G. Lyketsos, Hochang B. Lee
An overview of current knowledge regarding depression inAD for the clinician is provided and a practical discussion of the detection, evaluation, quantification, differential diagnosis and treatment of depression in AD is discussed.
American Journal of Geriatric PsychiatryMetaanalysis of Randomized Trials of the Efficacy and Safety of Donepezil, Galantamine, and Rivastigmine for the Treatment of Alzheimer Disease
131 Citations2004Craig Ritchie, David Ames +2 more
All three commonly used drugs for Alzheimer disease had similar cognitive efficacy, with donepezil and rivastigmine showing a dose effect across the dosing levels studied, however, both galantamine and rivetigmine were associated with a greater risk of trial dropout than placebo, especially at higher dosed levels.
Alzheimer Disease & Associated DisordersBehavioral Treatment of Depression in Patients with Dementia
97 Citations1994Linda Teri
Results thus far indicate that behavioral treatment is effective in reducing depression in patients with Alzheimer disease and in reducing the level of depression in their caregivers.
Alzheimer Disease & Associated DisordersRealistic Expectations: The Management of Severe Alzheimer Disease
60 Citations2003Roger Bullock, Gerry Hammond
An overview of the natural history, current therapy, and diagnostic scales of AD, focusing on management of patients with severe AD, is provided.
NeuropsychobiologyQuetiapine Treatment for Behavioral and Psychological Symptoms in Patients with Senile Dementia of Alzheimer Type
41 Citations2004Tokumi Fujikawa, Terumichi Takahashi +5 more
Data indicate that quetiapine is effective in controlling BPSD with favorable adverse-event profiles and significant improvements were seen in the CMAI total score and in the BEHAVE-AD subscales of delusions, activity disturbances, aggressiveness, diurnal rhythm disturbances and inThe BEHAve-AD overall severity.
The Journal of Clinical PsychiatryBehavioral and Psychological Symptoms in Patients With Dementia as a Target for Pharmacotherapy With Risperidone
31 Citations2004Jonathan Rabinowitz, Ira R. Katz +4 more
The data suggest that risperidone is more effective than placebo in treating a variety of symptoms associated with dementia.
PubMedUse of atypical antipsychotic drugs in patients with dementia.
31 Citations2003Charles D Motsinger, Gregory A Perron +1 more
Informed use of atypical antipsychotic drugs allows family physicians to greatly improve quality of life in elderly patients with dementia and behavior disturbances.
Aging Clinical and Experimental ResearchClinical aspects of Alzheimer’s disease
27 Citations2001Angelo Bianchetti, Marco Trabucchi
Alzheimer’s disease is the most common of the dementing disorders, and disease progression is highly variable, and median survival after the onset of dementia ranges from 5 to 9.3 years.
Neuroscience Research CommunicationsBehavioural and psychological symptoms of dementia: clinical aspects
13 Citations2004Angelo Bianchetti, Marco Trabucchi
Antidepressant and neuroleptics are the most frequently used drugs in the treatment of BPSD, even if the number of well designed controlled studies are limited.
Journal of Geriatric Psychiatry and NeurologyPharmacologic Management of Psychosis in the Elderly: A Critical Review
11 Citations2003Nicholas Hoeh, L. Gyulai +2 more
There is evidence of the efficacy of antipsychotic medications to manage psychotic symptoms in elderly patients, however, the absence of published evidence from RCTs in primary psychotic and affective disorders, and the limited evidence in the neurodegenerative illnesses, is notable.
Archives of Internal MedicineMedical Treatment of Acute Illnesses in End-Stage Dementia—Reply
10 Citations2003Jenny T. van der Steen, Marcel E. Ooms +3 more